Two Years After CanG: What the EKOCAN Report Really Means for Accessories Wholesale

If you've read the 222-page EKOCAN interim report, placed the EUDA European Drug Report 2025 next to it, and then cross-referenced the 2025 Police Crime Statistics with the status of Pillar 2, you have a lot of numbers. But what do they mean? I worked through the six most relevant primary sources, not for political analysis, but to answer a clear question: What does this mean for someone selling cannabis accessories wholesale? The short answer: Three parallel sales channels are emerging, each with completely different accessory needs. Those who understand this can align their product range strategically. Those who ignore it will sell into the wrong channel.

Seven Points from 222 Pages of EKOCAN

Consumption is stable. After two years of legalization, consumption prevalence among adults and youth has not increased—a DIW study from May 2026 independently confirms this. Home cultivation is growing massively, from 5.4% to 21.4% of consumers, an increase of 316% compared to the first half of 2024, and no other channel comes close to this growth. Cannabis Social Clubs (CSCs) remain small, with only 3.5% of consumers sourcing via social clubs, even though around 400-plus cultivation associations are approved, but only about 86 are operational. Online pharmacies dominate the market; telemedicine and a prescription explosion of plus 3,300% make this channel the largest legal-commercial market, with around 200 tons of medicinal cannabis in 2025 at an average THC content of 25%. The decline of the black market is not substantiated; Professor Sinn from the University of Osnabrück calls this thesis at most a preliminary working hypothesis. Early intervention is collapsing because counseling services are declining. And Pillar 2 is coming slower than expected; since June 2025, the KCanWV governs research, not specialty shops, and the Ministry of Health's draft bill is still pending.

Three Channels, Three Assortment Strategies

The EKOCAN report shows something rarely heard in the political debate: Legalization didn't create one market—it created three. And each operates differently.

The first channel is Cannabis Social Clubs, with a 3.5% market share. That sounds small, but it only measures where consumers currently buy, not where clubs will be in the future. Around 400-plus cultivation associations are approved, but only about 86 are operational. The gap is easily explained: Between approval and first harvest lies six to nine months. The 314 non-operational clubs are preparing and need equipment now. The German Cannabis Industry Association expects up to 13,000 clubs long-term. Whether that is realistic remains to be seen, but the 400-plus approved clubs are existing legal entities with procurement budgets. They are buying today. What a club needs are grinders in bulk commercial grade, precision scales for dosing and member distribution, storage containers that are light-proof, odor-proof, and Boveda-compatible, EU-compliant and GPSR child-resistant packaging, cleaning and hygiene products, and vaporizers for in-club consumption rooms, if approved. The opportunity lies in accompanying clubs from formation to first harvest and retaining them long-term through starter packages, compliance consulting, and recurring orders for consumables.

The second channel is online pharmacies, the largest commercial market. 200 tons of medicinal cannabis in 2025, 1,300 strains from 58 suppliers, average 25% THC, and 35 teleclinics in Germany (ranked second worldwide) have drastically simplified prescription issuance. Every patient needs accessories: vaporizers with medical-grade design featuring precise temperature control and certification, dosing capsules for refilling, UV-protected and child-resistant storage with Boveda, and cleaning kits including alcohol, brushes, and replacement screens. The risk in this channel: the new CDU-led government has announced restrictions on telemedicine, and the BfArM's Health Outcomes Survey could bring new prescribing guidelines by September. Investing now in medical-device-compliant vaporizers positions you for higher quality standards.

The third and fastest-growing channel is home grow, with 21.4% of consumers and 316% growth. One in five consumers now grows their own, and home growers buy specialized equipment. What a grower needs: grinders with a fine grind for vaporizers (which allow higher margins than standard grinders), trimming shears made of medical-grade steel in ergonomic shape, curing jars made of glass with rubber seal and Boveda compatibility, Boveda packs in bulk, potting soil, fertilizer, tents and lamps as adjacent product ranges, and sieve sets for solventless extraction. The 2026 outdoor season is underway, and peak purchasing season falls in April and May.

The Numbers for Planning

The EUDA European Drug Report 2025 sizes the EU cannabis market at €12.1 billion with 24 million adult annual consumers. Germany is the largest single market. Using a conservative 25% German share, this suggests an accessories market volume between €300 and €500 million for Germany. The 2025 Police Crime Statistics report about 180,000 cannabis-related offenses, down 30% from the previous year—the largest absolute decline of any offense group. Fewer criminal proceedings mean more consumers buying legally, and everyone moving from illegal to legal markets becomes a potential accessories customer.

Pillar 2 and Its Scenarios

Pillar 2 is the biggest lever in the coming years—not because it arrives tomorrow, but because it creates a professional purchasing channel that doesn't exist today. The KCanWV has been in effect since June 2025 and governs research applications, not specialty shops. The BLE (Federal Office for Agriculture and Food) is the responsible authority for research applications; the Ministry of Health must present a draft bill for licensed specialty shops, and the industry expects this in the second half of 2026. Over 25 cities have expressed interest in model regions, and a five-year evaluation is legally mandated. What specialty shops will need: professional shop design with display cases and storage, a broad accessories assortment, compliance-certified products meeting GPSR, REACH, and the Medical Devices Regulation, and a repeat customer relationship with recurring orders.

Three scenarios are conceivable for 2027–2031: In the optimistic scenario, the draft bill comes in 2026, the first shops open in 2027, and scaling occurs from 2028 to 2030. In the realistic scenario, the draft arrives in the first half of 2027, pilot projects start in 2028, and nationwide rollout begins from 2030. In the pessimistic scenario, EU reservations or a change of government delay everything to 2029 or later. In all scenarios, the trend points in one direction: away from the pure medical market and toward regulated specialty shops. Those who build compliance structures and CSC contacts today will be the established supplier in two to three years.

Recommendations for Wholesalers

Six strategic recommendations can be derived. First, the product range should be organized by channel. Core products needed by all channels are grinders, storage containers, and cleaning kits. Channel-specific products include vaporizers for pharmacies, trimming shears for home grow, and scales for CSCs. Cross-sell products like Boveda, packaging, and cleaning solutions round out the assortment. Second, a CSC sales team should be built to contact clubs during formation, offer starter packages as bundles, and provide compliance consulting. Third, a medical-device portfolio should be expanded, because the pharmacy channel is regulatory the ans